Yasmin Kit
Product Images NDC 50419-402

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Yasmin (NDC 50419-402). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formulas (425be71d 812e 4a54 8dea Bb27eb6b4ecf 03)

Chemical structure diagram displaying the molecular structures of drospirenone and ethinyl estradiol, the active ingredients in Yasmin. The image shows two distinct steroidal structures labeled accordingly.*

FDA Label Image

Pregnancy Diagram (425be71d 812e 4a54 8dea Bb27eb6b4ecf 04)

A vertical effectiveness chart illustrating pregnancy rates per 100 women in one year based on contraceptive methods. The chart ranges from fewer than 1 pregnancy (most effective) to 85 or more pregnancies (least effective) and categorizes methods including implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, behavioral methods, and no birth control.*

FDA Label Image

Pill Pack Image (425be71d 812e 4a54 8dea Bb27eb6b4ecf 05)

Yasmin medication kit label showing a 28-day circular pill layout divided into 4 weeks. The label includes the drug name Yasmin and active ingredients drospirenone and ethinyl estradiol with strength 3 mg/0.03 mg indicated. The arrows mark a starting point and guidance for daily pill use in sequence.*

FDA Label Image

Blood Clot Diagram (425be71d 812e 4a54 8dea Bb27eb6b4ecf 06)

A horizontal bar chart comparing the number of women developing a blood clot out of 10,000 women-years across four groups: Non-Pregnant Non-COC users (1 to 5), COC users (3 to 9), Pregnancy (5 to 20), and Postpartum (12 weeks only) with the highest range (40 to 65).*

FDA Label Image

Trade Carton (425be71d 812e 4a54 8dea Bb27eb6b4ecf 07)

Yasmin kit packaging label showing drospirenone and ethinyl estradiol tablets, 3 mg / 0.03 mg strength. The label includes the Bayer logo, product name, active ingredients, dosage form as tablets, and the quantity of 3 units. The packaging indicates oral use and includes a barcode and regulatory information.*

FDA Label Image

50419 0402 01 Splimage30 B8195c0a

Yasmin tablet containing drospirenone and ethinyl estradiol shown front and back. The front side features an embossed hexagon surrounding the letters 'DO'. The tablet is round, beige, and measured against a millimeter scale. This image represents one dosage form within the Yasmin kit by Bayer HealthCare Pharmaceuticals.*

FDA Label Image

50419 0402 01 Splimage30 Bb195dea

White, round tablet imprinted with "DP" inside a hexagonal outline on one side and plain on the other side, identified as part of Yasmin (drospirenone and ethinyl estradiol) kit by Bayer HealthCare Pharmaceuticals Inc.*

FDA Label Image

Image 01

A forest plot showing hazard ratios and odds ratios from various cohort and case-control studies, including Ingeinix, EURAS, LASS, FDA-funded, Danish studies, MEGA study, German case-control, PharMetrics, and GPRD study for non-fatal idiopathic cases. The x-axis is logarithmic, ranging from 0.1 to 10, with a reference line at 1 for comparison.*

FDA Label Image

Image 02

A bar chart depicting the risk of blood clots per 10,000 women years (WY) across four groups: Non-Pregnant Non-COC users, COC (combined oral contraceptive) users, Pregnant women, and Postpartum women at 12 weeks. The chart shows increasing risk ranges from 1 to 5, 3 to 9, 5 to 20, and 40 to 65 respectively.*

FDA Label Image

Image 03

A forest plot titled 'Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives' comparing ever COC use versus never COC use and current COC use versus never use. The chart displays study names and years on the left, effect estimates with confidence intervals plotted as horizontal lines with points, and numerical odds ratios (OR), relative risks (RR), and hazard ratios (HR) with confidence intervals on the right. The x-axis is labeled 'Effect Estimate' ranging from -1.50 to 2.00, with a vertical reference line at 1.00.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.